Ignite Creation Date:
2025-12-24 @ 11:50 AM
Ignite Modification Date:
2025-12-30 @ 4:24 PM
Study NCT ID:
NCT06276361
Status:
COMPLETED
Last Update Posted:
2025-09-08
First Post:
2024-02-16
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Pharmacokinetics, Safety and Tolerability of Different Formulations and Dose Strengths of Quarterly Risperidone (QUAR) in Patients With Schizophrenia
Sponsor:
Rovi Pharmaceuticals Laboratories
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-09-26
Start Date Type:
ACTUAL
Primary Completion Date:
2025-07-07
Primary Completion Date Type:
ACTUAL
Completion Date:
2025-07-07
Completion Date Type:
ACTUAL
First Submit Date:
2024-02-16
First Submit QC Date:
None
Study First Post Date:
2024-02-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-09-01
Last Update Post Date:
2025-09-08
Last Update Post Date Type:
ESTIMATED